[go: up one dir, main page]

WO2009100035A3 - Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) - Google Patents

Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) Download PDF

Info

Publication number
WO2009100035A3
WO2009100035A3 PCT/US2009/032894 US2009032894W WO2009100035A3 WO 2009100035 A3 WO2009100035 A3 WO 2009100035A3 US 2009032894 W US2009032894 W US 2009032894W WO 2009100035 A3 WO2009100035 A3 WO 2009100035A3
Authority
WO
WIPO (PCT)
Prior art keywords
foxp3
agonists
antagonists
interleukin
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/032894
Other languages
French (fr)
Other versions
WO2009100035A2 (en
Inventor
Fu-Dong Shi
Deborah A. Young
Mary Collins
Timothy Vollmer
Ruolan Liu
Wenhua Piao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Catholic Healthcare West
Original Assignee
Wyeth LLC
Catholic Healthcare West
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC, Catholic Healthcare West filed Critical Wyeth LLC
Publication of WO2009100035A2 publication Critical patent/WO2009100035A2/en
Publication of WO2009100035A3 publication Critical patent/WO2009100035A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods of modulating the level and activity of Tregs and Foxp3 using modulators of IL-21/IL-21 R, i.e., IL-21/IL-21 R agonists (i.e., IL-21 agonists and IL-21R agonists) and IL-21/IL-2 I R antagonists (i.e., IL-21 antagonists and IL-21 R antagonists), are disclosed. IL-21 /IL-21 R agonists and antagonists can be used to enhance immunity or induce immune suppression in vivo, ex vivo and/or in vitro, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, cancers, and infectious disorders.
PCT/US2009/032894 2008-02-01 2009-02-02 Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) Ceased WO2009100035A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2558608P 2008-02-01 2008-02-01
US61/025,586 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009100035A2 WO2009100035A2 (en) 2009-08-13
WO2009100035A3 true WO2009100035A3 (en) 2009-12-23

Family

ID=40602393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032894 Ceased WO2009100035A2 (en) 2008-02-01 2009-02-02 Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Country Status (1)

Country Link
WO (1) WO2009100035A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125717B (en) * 2017-09-08 2022-02-22 江苏苏博生物医学股份有限公司 Autologous whole cell vaccine formula for treating chronic diseases and preparation method thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
MXPA05000655A (en) 2002-07-15 2006-02-22 Harvard College Methods and compositions for modulating t helper (th.
EP2184298A1 (en) 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
GT200600148A (en) 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
WO2010104617A2 (en) * 2009-01-23 2010-09-16 Salvatore Albani Novel methods to induce a state of immune tolerance
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
KR101931628B1 (en) * 2010-06-18 2019-03-13 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Pla2g16 as a target for antiviral compounds
PL3636274T3 (en) 2011-01-18 2025-01-20 Bioniz Therapeutics, Inc. Compositions for modulating gamma-c-cytokine activity
CN102949722A (en) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 Novel pharmaceutical composition based on p38 inhibitor and cell growth factor
CA2915882C (en) * 2013-06-27 2022-12-06 Monash University Il-21 binding proteins and uses thereof
EP3054978B1 (en) 2013-10-08 2019-03-06 Georgia State University Research Foundation, Inc. Compositions including il-18 and il-22 and their use in anti-viral therapies
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2015110930A1 (en) * 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
US20170204089A1 (en) 2014-08-04 2017-07-20 Drexel University Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
US10030058B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulating gamma-C-cytokine activity
US20190391152A1 (en) 2016-05-16 2019-12-26 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
EP3976182A4 (en) 2019-05-03 2023-01-18 Bioniz, LLC MODULATING THE SIGNALING EFFECTS OF CYTOKINE GAMMA-C FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN116083483A (en) * 2021-10-12 2023-05-09 百奥赛图江苏基因生物技术有限公司 IL21 gene humanized non-human animal and construction method and application thereof
CN117904290B (en) * 2023-12-13 2024-07-23 暨南大学 Application of IL-21R in the preparation of diagnostic and prognostic prediction products and therapeutic drugs for non-alcoholic steatohepatitis-related liver cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084835A2 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
WO2005067956A2 (en) * 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084835A2 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
WO2005067956A2 (en) * 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PELUSO ILARIA ET AL: "IL-21 counteracts the regulatory T cell-mediated suppression of human CD4(+) T lymphocytes", JOURNAL OF IMMUNOLOGY, vol. 178, no. 2, January 2007 (2007-01-01), pages 732 - 739, XP002528645, ISSN: 0022-1767 *
PIAO W -H ET AL: "IL-21 modulates CD4(+) CD25(+) regulatory t-cell homeostasis in experimental autoimmune encephalomyelitis", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 67, no. 1, January 2008 (2008-01-01), pages 37 - 46, XP002528644, ISSN: 0300-9475 *
PIAO WEN-HUA ET AL: "IL-21 modulates CD4(+)CD25(+) regulatory T cell homeostasis in experimental autoimmune encephalomyelitis", NEUROLOGY, vol. 70, no. 11, Suppl. 1, March 2008 (2008-03-01), & 60TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; CHICAGO, IL, USA; APRIL 12 -19, 2008, pages A31, XP009116916, ISSN: 0028-3878 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125717B (en) * 2017-09-08 2022-02-22 江苏苏博生物医学股份有限公司 Autologous whole cell vaccine formula for treating chronic diseases and preparation method thereof

Also Published As

Publication number Publication date
WO2009100035A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2009100035A3 (en) Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
EP2224921A4 (en) MODULATION OF THE IMMUNE RESPONSE
MX2009008918A (en) Activation of human antigen-presenting cells through clec-6.
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011139688A3 (en) Methods for generating cardiomyocytes
SG178991A1 (en) Anti-gitr antibodies
CA2866116C (en) Expansion of alloantigen-reactive regulatory t cells
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2013040371A3 (en) Targeting the tumor microenvironment using manipulated nkt cells
EP3159337A3 (en) Substituted benzoazepines as toll-like receptor modulators
SG10201804330YA (en) Engineered high-affinity human t cell receptors
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
CA140394S (en) Suspended rail for carrying trolleys
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2011022508A3 (en) Substituted benzoazepines as toll-like receptor modulators
WO2014012001A3 (en) Use of cart19 to deplete normal b cells to induce tolerance
MX2011003473A (en) Oral care compositions.
MX375079B (en) Integrin î±vî²8 neutralizing antibody
WO2009134429A3 (en) Methods and compositions for modulating immunological tolerance
PH12014501369A1 (en) Oral care compositions
IN2015DN04209A (en)
WO2012012570A3 (en) High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon
PH12013501154A1 (en) Fluid oral care compositions
MY161460A (en) Elastomeric dental floss
MY171313A (en) Oral care compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708714

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09708714

Country of ref document: EP

Kind code of ref document: A2